A Phase I/II Study of GX15-070MS in Untreated CLL
This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.
Chronic Lymphocytic Leukemia
DRUG: GX15-070MS|DRUG: GX15-070MS
Determine the recommended Phase II dose of GX15-070MS administered as a 60-minute and/or 3-hour infusion every 2 to 3 weeks, 14 days
Estimate the response rate of previously-treated patients with CLL at the recommended Phase II dose of GX15-070MS administered as a 60-minute and/or 3-hour infusion every 2 to 3 weeks., 14 days
Both 1 hour and 3 hour infusions of obatoclax every 3 weeks will be evaluated in ascending doses.